Skip to main content
BLLN logo

BLLN · BillionToOne, Inc.

Track BLLN — free
$90.52 -6.99 (-7.16%)
Market Cap
$4.66B
Shares
47.77M
Volume · Nov 18 503.64K Avg daily vol (3M) 616.99K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$97.50 Open$99.12 Day$94.11–100.01 52W close$64.03–149.97 Avg vol 30d604K Short int3.0M · 6.2% of shares · 6.7d Short vol68% Last earningsNov 4, 2026 DataNov 2025–Nov 2026 Filing10-Q · Nov 4

Up next

Mar 3, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 10
Investor event
CEO sees oncology volumes above 100%, prenatal growth near 20%

Billion to One CEO Ozan Atay said a head-to-head study detected 50% more actionable therapies, oncology test volumes were growing faster than 100% year over year, and prenatal could sustain about 20% growth.

5 source passages
Ozan Atay, CEO I'm Doug Schenkel with UBS, and it's my pleasure to welcome Okazan Atay, co-founder and chief executive officer of Billion to One. We have been able to show with a head-to-head study, you know, against the incumbents, that we can detect 50% more actionable therapies. test volumes are growing faster than 100% year over year, and we are seeing acceleration. the contribution can get to still about 20% growth on that business Open the document at this passage
Nov 4
Earnings call
47% revenue growth; Northstar Clear launches December 15th

Billion to One reported third-quarter revenue of $123.0 million, up 47% year-over-year, raised its 2026 revenue outlook to $460 million to $470 million, and will launch Northstar Clear on December 15th.

5 source passages
Earlier today, Billion to One released financial results for the third quarter, and it's September 30th, 2026. Total revenue in the third quarter of 2026 was $123.0 million, compared to $83.5 million in the third quarter of 2025. On rapid growth, prenatal revenue was up 42%. And oncology revenue was up 96%, resulting in total Q3 revenue growth of 47% year-over-year. We are raising our 2026 total revenue outlook to a range of $460 million to $470 million from $450 million to $465 million previously. We are excited to announce that Northstar Clear, our tissue-free MRD test, will be commercially launching on December 15th. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue grows 63%, delivered tests rise 34%

BillionToOne reported nine-month revenue growth of 63% for the nine months ended September 30, 2026, driven by 34% growth in delivered and billable tests to approximately 590,000 and a 22% increase in Overall ASP. Revenue increased $131.8 million.

Revenue $122.98M ▲ 47.2% Net income $17.39M ▲ 204.5% Diluted EPS $0.32 ▲ 220.0%
Read from the MD&A section
2 source passages
BillionToOne is transforming healthcare by redefining molecular diagnostics. Revenue increased $131.8 million, or 63%, for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025. This increase was driven primarily by a 34% increase in the total volume of delivered and billable tests to approximately 590,000 for the nine months ended September 30, 2026 from approximately 441,000 for the nine months ended September 30, 2025. The increase in revenue was also attributable to an increase in our Overall ASP of 22%. Open the document at this passage
Nov 4
Current report 8-K
Raises Revenue Guidance After 47% Third-Quarter Growth

BillionToOne reported third-quarter revenue of $123.0 million, up 47%, and raised full-year 2026 revenue guidance to $460.0 million to $470.0 million from $450.0 million to $465.0 million. Net income was $17.4 million, or $0.32 per diluted share.

Financial results
3 source passages
Total revenue of $123.0 million in the third quarter of 2026, compared to $83.5 million in the third quarter of 2025, an increase of 47%. BillionToOne now expects full year 2026 total revenue of $460.0 million to $470.0 million, representing growth of 51% to 54% compared to full year 2025. This compares to the company's previous guidance of $450.0 million to $465.0 million. Net income in the third quarter of 2026 was $17.4 million, or $0.32 per diluted share, compared to net income of $1.5 million, or $0.10 per diluted share, in the third quarter of 2025. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$436.87M
Trailing 12 months
Net income (TTM)
$49.39M
Trailing 12 months
Revenue growth YoY
+47.2%
Year over year
Operating margin
10.2%
Trailing 12 months
P / E (TTM)
77.4
Trailing earnings · reciprocal yield 1.3%
FCF yield
0.7%
TTM · current market cap
Return on invested capital
47.2%
Trailing 12 months
Net cash
$472.53M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+245.1%
Year over year · more shares
Price change (1Y)
+4.5%
Trailing year
Short interest
6.2%
Latest settlement · 6.7 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. BillionToOne delivered 47% revenue growth, 25% test-volume growth, 18% ASP growth, 96% oncology revenue growth, a 71% gross margin, GAAP operating income of $11.0 million and $8.6 million of free cash flow, while raising guidance and validating Unity Fetal Risk Screen prospectively. Risks include higher operating expenses, anticipated mix-related cost-per-test pressure, modest initial Northstar Clear revenue in 2027, and uncertainty surrounding PAMA reimbursement changes.

Bullish
  • + Third-quarter revenue grew 47%, test volume increased 25%, and overall ASP rose 18% year-over-year. new
  • + Oncology revenue grew 96% year-over-year to $17.1 million. new
  • + Management raised 2026 revenue guidance to $460 million-$470 million, representing 51%-54% growth. new
  • + Northstar Clear, a pan-cancer tissue-free MRD test, is scheduled to launch commercially on December 15, 2026. new
  • + Northstar Response agreed with the tumor-informed assay on 94% of sequential pairs, and clinical records supported Response's findings in all four divergent cases. new
Bearish
  • − Operating expenses increased 56% year-over-year to $76.1 million as R&D and SG&A spending increased. new
  • − Cost per test increased as oncology grew faster than prenatal, and management anticipates further mix-driven cost pressure. new
  • − Northstar Clear's revenue contribution is expected to remain modest in 2027. new
  • − PAMA reimbursement changes face implementation uncertainty, and the aneuploid code used by the company is expected to decrease. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −0%
below
Price vs 50-day avg −9%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 39%
mid-range
Momentum
relative strength
Strong
1-month return −6%
trailing
6-month return 0%
trailing
YTD return +19%
this year
Relative strength +3%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $107 › 200d $98 — 50d above 200d
Institutional flow Accumulating
+12% holders QoQ · +52 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.22% of shares out · ▲ +1.3% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
175 holders — near 1-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Excellent
Revenue growth +100%
Y/Y
Gross margin 68%
expanding
EPS growth +103%
Y/Y
Free cash flow $15.7M
Valuation P/E 101.4
rich
Balance sheet $438.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 87%
annualized · 1-yr
Max drawdown −51%
past year
ATR 6.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 2
Latest guidance · from the 8-K filed Nov 4, 2026
Total revenue · full year 2026 Raised $460M – $470M
Aug 5, 2026 $450M – $465M changed to Nov 4, 2026 $460M – $470M
prior FY $305.11M midpoint +52.4% Y/Y
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Gross margin · forward looking / long term 70% – 80%
Prior guidance period ended · from the 8-K filed Dec 9, 2025
Full year 2025 total revenue · full year 2025 $293M – $299M
Fourth quarter 2025 revenue · fourth quarter 2025 $84M – $90M
Guided vs delivered · last 2 settled
Full year 2025 total revenue full year 2025
guided $293M – $299M
$305.11M Beat +3.1%
Fourth quarter 2025 revenue fourth quarter 2025
guided $84M – $90M
$96.05M Beat +10.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−0% Neutral
Price vs 50-day avg
−9% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
39% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $107 › 200d $98 — 50d above 200d
Institutional flow Accumulating
+12% holders QoQ · +52 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.22% of shares out · ▲ +1.3% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
175 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $64 Now $98 · 39% Range high $150
vs 200-day avg 0% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP 42.17M Six Months Ended June 30, 2026 —
EBITDA 20.27M Six Months Ended June 30, 2026 —
Free cash flow non-GAAP 16.05M Six Months Ended June 30, 2026 —
Overall ASP $551 Three Months Ended June 30 —
Overall ASP change 21% the three months ended June 30, 2026 filing —
Overall Cost Per Test change 3% the three months ended June 30, 2026 filing —
Total tests accessioned 197,000 Three Months Ended June 30 —
Total tests delivered 196,000 the second quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BLLN
BillionToOne, Inc.
this stock
$4.66B +19.1% +100.0% 101.4 6.2%
TMO
Thermo Fisher Scientific Inc.
$254.47B +18.5% +14.5% 36.2 1.3%
DHR
Danaher Corp
$158.84B -1.4% +8.5% 36.9 1.2%
IDXX
Idexx Laboratories Inc
$54.38B +2.0% +10.4% 46.5 3.0%
A
Agilent Technologies, Inc.
$48.55B +26.6% +6.4% 33.9 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
175
% held
38.6%
Net QoQ
+3.2M sh
Top holder
ADAMS STREET PARTNERS LLC
Held Float
View
Held by Funds
Fund positions
115
View
Short & Settlement
Short Interest Rising
Shares short
3.0M
Days to cover
6.7d
Change
+38.1K sh
View
Short Volume
Short vol %
68%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
762
Value
$81.1K
As of
Oct 1, 2026
View
Off-Exchange
Off-exchange %
48.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$305.1M
Net income (FY)
$7.5M
EPS diluted
$0.14
View
Buybacks
Remaining
shares 3.3M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
16

Billion to One CEO Ozan Atay said a head-to-head study detected 50% more actionable therapies, oncology test volumes were growing faster than 100% year over year, and prenatal could sustain about 20% growth.

View
Proposed Sales
Value
$2.3M
Shares
20.0K
Filed
Nov 2, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
BillionToOne to Report Third Quar…
Published
Oct 14, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
BLLN -13.0% -5.8% -0.3% -14.0% +19.1%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY -10.6% -1.0% +2.6% -10.9% +11.7%

Capital returns

Buyback program · as of Nov 5, 2025
Authorized
—
Spent (derived)
—
Remaining
shares 3.30M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 2070849 CUSIP 090168105 13F (30d) 166 filings 162 filers Visit website Investor relations